Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | PRKX | P51817 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | CLK2 | P49760 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27216855 | 1.00 | MAPK1 (0.47) | MAPK1HTTMKNK1EGFRCCNA2 | |
| SCHEMBL27216839 | 0.85 | CDC7 (0.43) | MKNK1EGFRPRKD3NPC1RAB9A | |
| SCHEMBL30936717 | 0.85 | CDC7 (0.43) | MKNK1EGFRPRKD3NPC1RAB9A | |
| SCHEMBL30936725 | 0.83 | MAOB (0.40) | MKNK1GRM4TGFBR1 | |
| SCHEMBL27216867 | 0.83 | MAOB (0.40) | MKNK1GRM4TGFBR1 | |
| SCHEMBL30936711 | 0.80 | TGFBR1 (0.38) | CDK2GRM4TGFBR1 | |
| SCHEMBL30936735 | 0.80 | MAOB (0.43) | MAPK1EGFRBRAFPTGS1PTGS2 | |
| SCHEMBL27216835 | 0.80 | MAOB (0.43) | MAPK1EGFRBRAFPTGS1PTGS2 | |
| SCHEMBL27216850 | 0.80 | TGFBR1 (0.38) | CDK2GRM4TGFBR1 | |
| SCHEMBL22655491 | 0.78 | ADORA3 (0.35) | MKNK1BRAFROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158404-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158404-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | MAPK1 2125/4885HTT 1193/4885MKNK1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.